Enjoy complimentary customisation on priority with our Enterprise License!
The post-traumatic stress disorder therapeutics market size has the potential to grow by USD 909.86 million during 2020-2024, and the market’s growth momentum will accelerate during the forecast period.
This report provides a detailed analysis of the market by product (antidepressants, anxiolytics, and other PTSD therapeutics) and geography (APAC, Europe, MEA, North America, and South America). Also, the report analyzes the market’s competitive landscape and offers information on several market vendors, including AstraZeneca Plc, Azevan Pharmaceuticals Inc., Bionomics Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck AS, Mylan NV, Neurocrine Biosciences Inc., Novartis International AG, and Pfizer Inc.
The market is fragmented with the presence of numerous international and regional vendors. However, the market has been recording an increase in mergers and acquisitions, which is helping vendors in expanding their presence in different regions and product portfolios for achieving economies of scale. H. Lundbeck AS, Mylan NV, Neurocrine Biosciences Inc., Novartis International AG, and Pfizer Inc. are some of the major market participants. Although the rising prevalence of post-traumatic stress disorder (PTSD) will offer immense growth opportunities, the lack of quality research in PTSD treatment will challenge the growth of the market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
To help clients improve their market positions, this post-traumatic stress disorder therapeutics market forecast report provides a detailed analysis of the market leaders and offers information on the competencies and capacities of these companies. The report also covers details on the market’s competitive landscape and offers information on the products offered by various companies. Moreover, this post-traumatic stress disorder therapeutics market analysis report also provides information on the upcoming post-traumatic stress disorder therapeutics trends and challenges that will influence market growth. This will help companies create strategies to make the most of future growth opportunities.
This report provides information on the production, sustainability, and prospects of several leading companies, including:
North America was the largest post-traumatic stress disorder therapeutics market in 2019, and the region will offer several growth opportunities to market vendors during the forecast period. The rising spending on the treatment of anxiety disorders, the growing initiatives to increase awareness about PTSD, and the increasing number of trauma-related cases such as assaultive violence will significantly influence post-traumatic stress disorder therapeutics market growth in this region.
Over 38% of the market’s growth will originate from North America during the forecast period. The US and Canada are the key markets for post-traumatic stress disorder therapeutics in North America. Market growth in this region will be slower than the growth of the market in APAC.
The high prescriptions of SSRIs, as these drugs are only approved for the treatment of PTSD, and the increasing awareness about the clinical benefits of antidepressants are contributing to the post-traumatic stress disorder therapeutics market share growth. Branded and generic ZOLOFT (sertraline) and PAXIL (paroxetine) are the first-line medications for adults with PTSD.
Market growth by the antidepressants segment will be faster than the growth of the market by the other segments. This report provides an accurate prediction of the contribution of all the segments to the growth of the post-traumatic stress disorder therapeutics market size.
The rising prevalence of PTSD has been identified as one of the key post-traumatic stress disorder therapeutics market. Approximately 6-8 out of 10 people that are victims of severe traumatic events develop PTSD. Events such as assaultive violence, childhood maltreatment, witnessing injury/trauma to others, serious accidents and illnesses, unexpected death of family member or friend, and natural disasters can cause PTSD. Therefore, the sales of many pharmacologic agents such as MDMA, ketamine, and glucocorticoids are gaining prominence and R&D focus. These agents are also being treated as novel pharmacotherapies for PTSD and several clinical trials are being conducted to check the effectiveness of these agents to treat PTSD in various phases. It is observed that MDMA enhances the therapeutic process for PTSD as it reduces fear and defensiveness, increases empathy and compassion, and enhances communication and introspection.
Executive Summary
Market Landscape
Market Sizing
Five Forces Analysis
Market Segmentation by Product
Customer landscape
Geographic Landscape
Drivers, Challenges, and Trends
Vendor Landscape
Vendor Analysis
Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
Get the report (PDF) sent to your email within minutes.